Trial Profile
A Randomized Feasibility Study Evaluating Temozolomide Chronotherapy for High Grade Glioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 05 Oct 2022 Planned End Date changed from 31 Jul 2023 to 14 Jul 2024.
- 05 Oct 2022 Planned primary completion date changed from 31 Jan 2023 to 14 Jul 2024.
- 02 Aug 2022 Planned End Date changed from 28 Feb 2023 to 31 Jul 2023.